StockData

Advanced Biomed vs Sera Prognostics

ADVB and SERA side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADVB and SERA compare

Sera Prognostics is the larger company, worth 20 times as much as Advanced Biomed ($76.5M against $3.8M).

Advanced Biomed scores higher on the StockData Score (8 against 5 for Sera Prognostics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADVBSERA
Size and price
Market cap$3.8M$76.5M
Share price$2.32$1.94
Change, 1 year−71.5%−23.9%
Change, 5 years–−82.0%
Beta (5Y)0.731.23
Employees12–
StockData Score
Total score8 (better)5
Valuation score2 (better)1
Growth score00
Performance score1 (better)0
Health score5 (better)4
Dividend score00
Valuation
P/E0.4×–
P/S–797×
P/B0.3× (better)1.5×
FCF yield–−37.9%
Growth
Revenue growth (TTM)–1.1%
Revenue growth, 5Y average–26.5%
Profitability
Operating margin–−38755%
Net margin–−34867%
FCF margin–−30199%
Return on equity84.8% (better)−49.7%
Return on invested capital–−124%
Financial health
Debt / equity0.000.00
Interest coverage–−5315.0×
Current ratio9.33 (better)1.88
Altman Z-score1.35 (better)−5.45
Piotroski F-score44
Dividends and buybacks
Buyback yield−6.5%0.00% (better)
Shareholder yield−6.5%0.00% (better)
Ownership
Held by institutions–43.2%
Held by insiders0.00%30.4%
Insider net buying, 12 months–−$524K
Short interest, % of float0.68%0.80%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.